Alirocumab and evolocumab, in addition to maximum tolerated statin therapy, are two human anti-PCSK9 monoclonal antibodies used in patients with familial and non-familial hypercholesterolemia or mixed dyslipidaemia who do not reach their therapeutic goals even with the highest tolerated doses of statins [206,207,208,209]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.